Trevi Therapeutics, Inc. TRVI Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.94M+27.3% | $6.19M-33.6% | $10.09M-10.1% | $9.39M-6.3% | $7.81M-11.3% | ||
| $4.97M+35.9% | $4.03M+38.1% | $3.83M+33.8% | $4.33M+32.6% | $3.66M+18.0% | ||
| $14.91M+30.0% | $10.22M-16.5% | $13.92M-1.2% | $13.72M+3.3% | $11.47M-3.7% | ||
| -$14.91M-30.0% | -$10.22M+16.5% | -$13.92M+1.2% | -$13.72M-3.3% | -$11.47M+3.7% | ||
| $1.7M+51.9% | $1.89M+124% | $2.1M+158% | $1.4M+50.7% | $1.12M+12.3% | ||
| -$13.21M-27.6% | -$8.33M+26.9% | -$11.82M+11.0% | -$12.32M+0.3% | -$10.35M+5.1% | ||
| -$20K-81.8% | -$16K— | -$15K+51.6% | -$21K-163% | -$11K-37.5% | ||
| -$13.19M-27.6% | -$8.32M+27.1% | -$11.8M+10.9% | -$12.3M+0.4% | -$10.34M+5.2% | ||
| -$0.090.0% | -$0.06+45.5% | -$0.08+38.5% | -$0.09+25.0% | -$0.09+18.2% | ||
| -$14.88M-30.1% | -$10.19M+16.5% | -$13.88M+1.2% | -$13.68M-3.3% | -$11.43M+3.7% | ||
| -$14.91M-30.0% | -$10.22M+16.5% | -$13.92M+1.2% | -$13.72M-3.3% | -$11.47M+3.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Trevi Therapeutics, Inc. profitable?
- Trevi Therapeutics, Inc. is not currently profitable: it reported a net loss of $45.6M over the trailing twelve months.
- What is Trevi Therapeutics, Inc.'s earnings per share?
- Trevi Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.32.
- Where does Trevi Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.